These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 34114372)

  • 1. A SMAD4-modulated gene profile predicts disease-free survival in stage II and III colorectal cancer.
    Szeglin BC; Wu C; Marco MR; Park HS; Zhang Z; Zhang B; Garcia-Aguilar J; Beauchamp RD; Chen XS; Smith JJ
    Cancer Rep (Hoboken); 2022 Jan; 5(1):e1423. PubMed ID: 34114372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of transforming growth factor beta (TGF-β) signaling axis molecules and E-cadherin in colorectal cancer.
    Lampropoulos P; Zizi-Sermpetzoglou A; Rizos S; Kostakis A; Nikiteas N; Papavassiliou AG
    Tumour Biol; 2012 Aug; 33(4):1005-14. PubMed ID: 22278155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of loss of heterozygosity and sub-cellular localization of SMAD4 varies with tumor stage in colorectal cancer.
    Jia X; Shanmugam C; Paluri RK; Jhala NC; Behring MP; Katkoori VR; Sugandha SP; Bae S; Samuel T; Manne U
    Oncotarget; 2017 Mar; 8(12):20198-20212. PubMed ID: 28423626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of SMAD4 Promotes Colorectal Cancer Progression by Recruiting Tumor-Associated Neutrophils via the CXCL1/8-CXCR2 Axis.
    Ogawa R; Yamamoto T; Hirai H; Hanada K; Kiyasu Y; Nishikawa G; Mizuno R; Inamoto S; Itatani Y; Sakai Y; Kawada K
    Clin Cancer Res; 2019 May; 25(9):2887-2899. PubMed ID: 30705034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Smad4-mediated signaling inhibits intestinal neoplasia by inhibiting expression of β-catenin.
    Freeman TJ; Smith JJ; Chen X; Washington MK; Roland JT; Means AL; Eschrich SA; Yeatman TJ; Deane NG; Beauchamp RD
    Gastroenterology; 2012 Mar; 142(3):562-571.e2. PubMed ID: 22115830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preliminary Study of the Role F-Box Protein 32 (FBXO32) in Colorectal Neoplasms Through the Transforming Growth Factor beta (TGF-β)/Smad4 Signalling Pathway.
    Yuan X; Zhang Z; Jiang K; Wang X; Li Y
    Med Sci Monit; 2018 Feb; 24():1080-1088. PubMed ID: 29465067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SMAD4 Loss in Colorectal Cancer Patients Correlates with Recurrence, Loss of Immune Infiltrate, and Chemoresistance.
    Wasserman I; Lee LH; Ogino S; Marco MR; Wu C; Chen X; Datta J; Sadot E; Szeglin B; Guillem JG; Paty PB; Weiser MR; Nash GM; Saltz L; Barlas A; Manova-Todorova K; Uppada SPB; Elghouayel AE; Ntiamoah P; Glickman JN; Hamada T; Kosumi K; Inamura K; Chan AT; Nishihara R; Cercek A; Ganesh K; Kemeny NE; Dhawan P; Yaeger R; Sawyers CL; Garcia-Aguilar J; Giannakis M; Shia J; Smith JJ
    Clin Cancer Res; 2019 Mar; 25(6):1948-1956. PubMed ID: 30587545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Smad4 inactivation predicts for worse prognosis and response to fluorouracil-based treatment in colorectal cancer.
    Kozak MM; von Eyben R; Pai J; Vossler SR; Limaye M; Jayachandran P; Anderson EM; Shaffer JL; Longacre T; Pai RK; Koong AC; Chang DT
    J Clin Pathol; 2015 May; 68(5):341-5. PubMed ID: 25681512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of SMAD4 alters BMP signaling to promote colorectal cancer cell metastasis via activation of Rho and ROCK.
    Voorneveld PW; Kodach LL; Jacobs RJ; Liv N; Zonnevylle AC; Hoogenboom JP; Biemond I; Verspaget HW; Hommes DW; de Rooij K; van Noesel CJ; Morreau H; van Wezel T; Offerhaus GJ; van den Brink GR; Peppelenbosch MP; Ten Dijke P; Hardwick JC
    Gastroenterology; 2014 Jul; 147(1):196-208.e13. PubMed ID: 24704720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SMAD4 gene mutation predicts poor prognosis in patients undergoing resection for colorectal liver metastases.
    Mizuno T; Cloyd JM; Vicente D; Omichi K; Chun YS; Kopetz SE; Maru D; Conrad C; Tzeng CD; Wei SH; Aloia TA; Vauthey JN
    Eur J Surg Oncol; 2018 May; 44(5):684-692. PubMed ID: 29551247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SMAD4 alteration associates with invasive-front pathological markers and poor prognosis in colorectal cancer.
    Oyanagi H; Shimada Y; Nagahashi M; Ichikawa H; Tajima Y; Abe K; Nakano M; Kameyama H; Takii Y; Kawasaki T; Homma KI; Ling Y; Okuda S; Takabe K; Wakai T
    Histopathology; 2019 May; 74(6):873-882. PubMed ID: 30636020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of reduced SMAD4 expression in patients with metastatic colorectal cancer under oxaliplatin-containing chemotherapy: a translational study of the AIO colorectal study group.
    Baraniskin A; Munding J; Schulmann K; Meier D; Porschen R; Arkenau HT; Graeven U; Schmiegel W; Tannapfel A; Reinacher-Schick A
    Clin Colorectal Cancer; 2011 Mar; 10(1):24-9. PubMed ID: 21609932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of SMAD4 from colorectal cancer cells promotes CCL15 expression to recruit CCR1+ myeloid cells and facilitate liver metastasis.
    Itatani Y; Kawada K; Fujishita T; Kakizaki F; Hirai H; Matsumoto T; Iwamoto M; Inamoto S; Hatano E; Hasegawa S; Maekawa T; Uemoto S; Sakai Y; Taketo MM
    Gastroenterology; 2013 Nov; 145(5):1064-1075.e11. PubMed ID: 23891973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A network-based predictive gene-expression signature for adjuvant chemotherapy benefit in stage II colorectal cancer.
    Cao B; Luo L; Feng L; Ma S; Chen T; Ren Y; Zha X; Cheng S; Zhang K; Chen C
    BMC Cancer; 2017 Dec; 17(1):844. PubMed ID: 29237416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimetastatic role of Smad4 signaling in colorectal cancer.
    Zhang B; Halder SK; Kashikar ND; Cho YJ; Datta A; Gorden DL; Datta PK
    Gastroenterology; 2010 Mar; 138(3):969-80.e1-3. PubMed ID: 19909744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The BMP pathway either enhances or inhibits the Wnt pathway depending on the SMAD4 and p53 status in CRC.
    Voorneveld PW; Kodach LL; Jacobs RJ; van Noesel CJ; Peppelenbosch MP; Korkmaz KS; Molendijk I; Dekker E; Morreau H; van Pelt GW; Tollenaar RA; Mesker W; Hawinkels LJ; Paauwe M; Verspaget HW; Geraets DT; Hommes DW; Offerhaus GJ; van den Brink GR; Ten Dijke P; Hardwick JC
    Br J Cancer; 2015 Jan; 112(1):122-30. PubMed ID: 25393365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphocytic infiltration in stage II microsatellite stable colorectal tumors: A retrospective prognosis biomarker analysis.
    Sanz-Pamplona R; Melas M; Maoz A; Schmit SL; Rennert H; Lejbkowicz F; Greenson JK; Sanjuan X; Lopez-Zambrano M; Alonso MH; Qu C; McDonnell KJ; Idos GE; Vignali M; Emerson R; Fields P; Guinó E; Santos C; Salazar R; Robins HS; Rennert G; Gruber SB; Moreno V
    PLoS Med; 2020 Sep; 17(9):e1003292. PubMed ID: 32970670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-34a mediates oxaliplatin resistance of colorectal cancer cells by inhibiting macroautophagy
    Sun C; Wang FJ; Zhang HG; Xu XZ; Jia RC; Yao L; Qiao PF
    World J Gastroenterol; 2017 Mar; 23(10):1816-1827. PubMed ID: 28348487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of TGF-beta1, its receptor TGFbetaRII, and Smad proteins in the progression of colorectal cancer.
    Gulubova M; Manolova I; Ananiev J; Julianov A; Yovchev Y; Peeva K
    Int J Colorectal Dis; 2010 May; 25(5):591-9. PubMed ID: 20165854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TIF1γ interferes with TGFβ1/SMAD4 signaling to promote poor outcome in operable breast cancer patients.
    Kassem L; Deygas M; Fattet L; Lopez J; Goulvent T; Lavergne E; Chabaud S; Carrabin N; Chopin N; Bachelot T; Gillet G; Treilleux I; Rimokh R
    BMC Cancer; 2015 Jun; 15():453. PubMed ID: 26040677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.